Open Access Open Access  Restricted Access Subscription Access

Indications, Mechanism of Action, Adverse Effects, Contraindications Toxicity of Ciproflaxacin

Muralinath E., Mr. Vonteru Munisekhar, Dr. P. Prabhavathi., K. Suparnalatha., M. Harshita., Dr. G. Rajeswari., Sri Devi K., Sailesh Sai., Guruprasad M.

Abstract


Ciprofloxacin is an antibiotic belonging to the fluoroquinolone class that is used to treat bacterial infections, specifically pneumonia and urinary tract infections. The FDA has approved ciprofloxacin for the treatment of gastrointestinal infections, lower respiratory tract infections, anthrax, plague, salmonellosis, skin, bone, joint infections, prostatitis, typhoid fever, and urinary tract infections. Additionally, patients with mixed infections or those with risk factors for Gram-negative infections can benefit from ciprofloxacin. In order to effectively manage patients' infectious infections, members of the interprofessional team must evaluate the indications, coverage, contraindications, and adverse event profile of ciprofloxacin, a broad-spectrum quinolone antibiotic.

 


Full Text:

PDF

References


Sharma, P. C., Jain, A., Jain, S., Pahwa, R., & Yar, M. S. (2010). Ciprofloxacin: Review on developments in synthetic, analytical, and medicinal aspects. Journal of Enzyme Inhibition and Medicinal Chemistry, 25(4), 577–589.

Zhang, H. L., Tan, M., Qiu, A. M., Tao, Z., & Wang, C. H. (2017). Antibiotics for treatment of acute exacerbation of chronic obstructive pulmonary disease: A network meta-analysis. BMC Pulmonary Medicine, 17, Article 196.

Bartolomé-Álvarez, J., & Solves-Ferriz, V. (2020). Increase in methicillin-resistant and ciprofloxacin-susceptible Staphylococcus aureus in osteoarticular, skin and soft tissue infections. Revista Española de Quimioterapia, 33(2), 143–144.

Meyerhoff, A., Albrecht, R., Meyer, J. M., Dionne, P., Higgins, K., & Murphy, D. (2004). U.S. Food and Drug Administration approval of ciprofloxacin hydrochloride for management of postexposure inhalational anthrax. Clinical Infectious Diseases, 39(3), 303–308.

Apangu, T., Griffith, K., Abaru, J., Candini, G., Apio, H., Okoth, F., Okello, R., Kaggwa, J., Acayo, S., Ezama, G., Yockey, B., Sexton, C., Schriefer, M., Mbidde, E. K., & Mead, P. (2017). Successful treatment of human plague with oral ciprofloxacin. Emerging Infectious Diseases, 23(3), 553–555.

Unemo, M., Lahra, M. M., Cole, M., Galarza, P., Ndowa, F., Martin, I., Dillon, J. R., Ramon-Pardo, P., Bolan, G., & Wi, T. (2019). World Health Organization Global Gonococcal Antimicrobial Surveillance Program (WHO GASP): Review of new data and evidence to inform international collaborative actions and research efforts. Sexual Health, 16(5), 412–425.

Coker, T. J., & Dierfeldt, D. M. (2016). Acute bacterial prostatitis: Diagnosis and management. American Family Physician, 93(2), 114–120.

Heras-Cañas, V., Gutiérrez-Soto, B., Almonte-Fernández, H., Lara-Oya, A., Navarro-Marí, J. M., Garrido-Frenich, A., Vázquez-Alonso, F., & Gutiérrez-Fernández, J. (2017). Antibiotic activity and concentrations in clinical samples from patients with chronic bacterial prostatitis. Actas Urológicas Españolas, 41(10), 631–638.

Wu, X. W., Ji, H. Z., & Wang, F. Y. (2015). Meta-analysis of ciprofloxacin in treatment of Crohn's disease. Biomedical Reports, 3(1), 70–74.

McDonald, E. M., Ram, F. S., Patel, D. V., & McGhee, C. N. (2014). Topical antibiotics for the management of bacterial keratitis: An evidence-based review of high quality randomised controlled trials. British Journal of Ophthalmology, 98(11), 1470–1477.

Mohamed, S., Elmohamady, M. N., Abdelrahman, S., Amer, M. M., & Abdelhamid, A. G. (2020). Antibacterial effects of antibiotics and cell-free preparations of probiotics against Staphylococcus aureus and Staphylococcus epidermidis associated with conjunctivitis. Saudi Pharmaceutical Journal, 28(12), 1558–1565.

Wiegand, S., Berner, R., Schneider, A., Lundershausen, E., & Dietz, A. (2019). Otitis externa. Deutsches Ärzteblatt International, 116(13), 224–234.

Edmunds, A. L. (2017). Otiprio: An FDA-approved ciprofloxacin suspension gel for pediatric otitis media with effusion. P&T, 42(5), 307–311.

Kaguelidou, F., Turner, M. A., Choonara, I., & Jacqz-Aigrain, E. (2011). Ciprofloxacin use in neonates: A systematic review of the literature. The Pediatric Infectious Disease Journal, 30(2), e29–e37.

Herold, C., Ocker, M., Ganslmayer, M., Gerauer, H., Hahn, E. G., & Schuppan, D. (2002). Ciprofloxacin induces apoptosis and inhibits proliferation of human colorectal carcinoma cells. British Journal of Cancer, 86(3), 443–448.

Aranha, O., Wood, D. P., & Sarkar, F. H. (2000). Ciprofloxacin-mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clinical Cancer Research, 6(3), 891–900.

Campoli-Richards, D. M., Monk, J. P., Price, A., Benfield, P., Todd, P. A., & Ward, A. (1988). Ciprofloxacin: A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs, 35(4), 373–447.

LeBel, M. (1988). Ciprofloxacin: Chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions. Pharmacotherapy, 8(1), 3–33.

Rehman, A., Patrick, W. M., & Lamont, I. L. (2019). Mechanisms of ciprofloxacin resistance in Pseudomonas aeruginosa: New approaches to an old problem. Journal of Medical Microbiology, 68(1), 1–10.

Güler, G., & Eraç, B. (2016). Investigation of fluoroquinolone resistance mechanisms in clinical Acinetobacter baumannii isolates. Mikrobiyoloji Bülteni, 50(2), 278–286.


Refbacks

  • There are currently no refbacks.